American Century Companies
TCRT icon

American Century Companies’s Alaunos Therapeutics TCRT Stock Holding History

American Century Companies’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-379
Closed -$150K – 1465
2014
Q3 		$150K Buy
+379
New +$183K ﹤0.01% 1388

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

American Century Companies's TCRT Position: Q4 2014 in Review

American Century Companies sold out of Alaunos Therapeutics (TCRT) in Q4 2014, closing a stake of 379 shares — an estimated $150K sold.

American Century Companies first reported a position in TCRT in Q3 2014 and held it in 1 quarter. The position peaked at $150K in Q3 2014. 85 funds tracked by Wall St. Rank hold TCRT as of Q4 2014.

  • American Century Companies reported no remaining Alaunos Therapeutics position as of Q4 2014 after selling out during the quarter.
  • American Century Companies sold 379 Alaunos Therapeutics shares in Q4 2014, an estimated $150K.
  • American Century Companies first reported a position in Alaunos Therapeutics in Q3 2014 and held it in 1 quarter.
  • American Century Companies's Alaunos Therapeutics position peaked at $150K in Q3 2014.
  • 85 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2014.

Based on American Century Companies's 13F filing for Q4 2014, filed 27 Jan 2015.